UK markets close in 4 hours 39 minutes

MDxHealth SA (0O8G.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.8200+0.0460 (+5.94%)
As of 05:18PM BST. Market open.
Full screen
Previous close0.7740
Open0.8200
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.8200 - 0.8200
52-week range0.8200 - 0.8200
Volume30
Avg. volumeN/A
Market cap453,385
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results

    NEWS RELEASE – INSIDE AND REGULATED INFORMATIONAugust 2, 2022, 4:00PM EDT / 22:00 CET Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results Solidifies leadership in the precision diagnostics urology marketProvides the most comprehensive menu of advanced molecular tests for urology in prostate cancerEnhances scale with best-in-class commercial channel into urology communityExact Sciences to take portion of initial payment i

  • Globe Newswire

    MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and Resignation of Director

    NEWS RELEASE - REGULATED INFORMATION 25 May 2022, 4:00 p.m. EDT / 22:00 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and Resignation of Director IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2022 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EG

  • Globe Newswire

    Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer

    NEWS RELEASE - REGULATED INFORMATIONMay 19, 2022, 4:00PM EDT / 22:00 CET Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx® for Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM – May 19, 2022 – – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial stage precision diagnostics company, announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Cov